CP 105696

Drug Profile

CP 105696

Latest Information Update: 19 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Transplant rejection
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 23 Jun 2000 Pfizer has merged with Warner-Lambert
  • 01 May 2000 Preclinical development for Transplant rejection in USA (Parenteral)
  • 01 May 2000 An in vitro study has been added to the pharmacodynamics section of transplant rejection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top